![]() ![]() In Bad Blood John Carreyrou tells the story of Theranos, and encourages us to consider the possible repercussions of our blind faith in a small group of brilliant individuals. By early 2017, the company’s value was zero and Holmes faced potential legal action from the government and her investors. ![]() Undaunted, the newspaper ran the first of dozens of Theranos’ articles in late 2015. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. There was just one problem: the technology didn’t work.įor years, Holmes had been misleading investors, FDA officials, and her own employees. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes’s worth at an estimated $4.7 billion. Review of Bad Blood: Secrets and Lies in a Silicon Valley Startup, by John Carreyrou. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup ‘unicorn’ promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Silicon Valley Has a Blind Spot, and John Carreyrou’s ‘Bad Blood’ Exposes It. The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end. ![]()
0 Comments
Leave a Reply. |